Lincoln Nadauld is the CEO of Culmination Bio, Inc., a precision medicine company focused on leveraging real-world clinical and genomic data to advance healthcare innovation. He is also the Co-Founder of Clarified Precision Medicine and previously served as Vice President and Chief of Precision Health & Academics at Intermountain Healthcare, where he led enterprise-wide initiatives in genomics, research, and graduate medical education across 24 hospitals and 200 clinics. Earlier, he was Executive Director of Intermountain Precision Genomics and a medical oncologist at Stanford University, where he also held an affiliated faculty role. Dr. Nadauld completed his fellowship in medical oncology at Stanford University after earning his undergraduate degree from Brigham Young University.